VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a leading provider of compliant digital health infrastructure and on-demand healthcare services across the United States, is pleased to provide an update on the Company’s recent operational performance and platform activity. Operational Highlights Exceeded 1.3 million in product orders placed ahead of schedule, surpassing our full-year 2025 guidanc ...

Core Insights - Hydreight Technologies Inc. reported a 132% year-over-year revenue increase in Q3 2025, marking its fourth consecutive quarter of profitability, driven by a diversified multi-vertical business model [3][6][23] Financial Performance - Q3 2025 GAAP revenue reached $10.52 million, a 132% increase compared to Q3 2024 - Topline revenue for Q3 was $12.83 million, up 110% year-over-year - Gross margin for Q3 was $2.33 million, an increase from $1.53 million in Q3 2024 - Adjusted EBITDA for Q3 was $620K, indicating continued operational improvement - GAAP net income for Q3 was $362K, compared to a net loss of $90K in Q3 2024 - For the first nine months of 2025, topline revenue was $26.71 million, up 61% year-over-year, and GAAP revenue was $20.44 million, up 70% year-over-year [6][8][23] Business Model and Growth - Hydreight operates a multi-vertical platform, with GLP-1 treatments accounting for approximately 28% of total platform activity, indicating a balanced and diversified approach [3][4] - The company has seen a 72% year-over-year increase in pharmacy orders, reflecting strong demand and treatment continuity [9] - The nurse network and clinic engagement have shown significant growth, with 198 new nurse sign-ups in Q3 2025, a 49% increase year-over-year [15] VSDHOne Platform - VSDHOne, launched in June 2025, has recorded approximately 295,000 product orders in Q3 and a total of about 887,000 orders since its launch [11][12] - The company aims to reach a target of approximately 1.3 million product orders for 2025, based on existing partner demand [13] Strategic Initiatives - The company is focused on enhancing its operational infrastructure, compliance, and automation processes as part of its 2026 framework [20][22] - Hydreight is expanding into additional treatment categories, including genetics and oral weight management, while also growing its partner ecosystem across the United States [22] Future Outlook - The company plans to release its 2026 guidance in mid-December, with a focus on stability, scale, and continued engagement with shareholders [23]

Core Insights - Hydreight Technologies Inc. has successfully closed a strategic partnership transaction with Perfect Scripts LLC, acquiring a 5% membership interest in exchange for 2,250,000 common shares valued at CAD$2.30 each [1][2] - The partnership aims to establish a 503B pharmacy in the U.S., allowing Hydreight to secure the lowest pricing for products sold by Perfect Scripts and its subsidiaries [2][8] - The U.S. compounding pharmacy sector is projected to grow from $6.31 billion in 2024 to $10.76 billion by 2033, indicating significant market potential for Hydreight's expansion [8] Company Overview - Hydreight operates a fully integrated mobile clinical network comprising over 2,500 nurses and 100 doctors across the U.S., providing healthcare services directly to patients [14] - The company has a 503B pharmacy network servicing all 50 states and is closely affiliated with a certified e-script and telemedicine provider network [14] - Hydreight's proprietary platform includes tools for accounting, documentation, sales, inventory, and patient data management, enhancing service delivery [14] Partnership Details - The transaction includes a Pro-Rata Investment Right allowing Hydreight to maintain its interest in Perfect Scripts and an option to acquire up to 40% of its membership interests [2][3] - Restrictions have been placed on the number of Hydreight shares that can be issued to Perfect Scripts, capping total shares at 12,000,000 [3] - A cash finder's fee of $258,750 was paid, representing 5% of the transaction's deemed value [4] Perfect Scripts Overview - Perfect Scripts LLC is the parent company of PerfectRx LLC and operates a 503A retail pharmacy in Iowa, with a distribution center in Florida [9][10] - PerfectRx is a HIPAA-compliant mail-order pharmacy capable of processing over 150,000 prescriptions daily, with infrastructure to handle demand surges [10][11] - The company utilizes its proprietary PerfectOS platform for digital prescription intake and real-time inventory management [10][11]

Core Insights - Hydreight Technologies Inc. reported significant financial growth in Q3 2025, with a focus on expanding its VSDHOne platform and achieving strategic objectives for 2026 [1][5][10] Financial Performance - For the first nine months of 2025, topline revenue reached CAD 26.71 million, a 61% increase year-over-year, while GAAP revenue was CAD 20.44 million, up 70% [5][7] - Q3 2025 topline revenue was CAD 12.83 million, marking a 110% increase compared to Q3 2024, with GAAP revenue at CAD 10.52 million, a 132% increase [5][7] - Q3 2025 gross margin improved to CAD 2.33 million from CAD 1.53 million in Q3 2024, and adjusted EBITDA was CAD 620K, indicating continued operational improvement [5][7] - The company reported a GAAP net income of CAD 362K in Q3 2025, a significant turnaround from a net loss of CAD 90K in Q3 2024 [5][7] Business Development - Hydreight processed approximately 295,000 VSDHOne product orders between July and September 2025, reflecting broad growth across various wellness verticals [5][10] - The nurse network expanded with 198 new sign-ups in Q3 2025, a 49% increase year-over-year, totaling 593 sign-ups in the first nine months of 2025, up 63% from 2024 [5][10] - Pharmacy orders increased by approximately 72% year-over-year, indicating sustained growth and broader adoption of services [5][10] Strategic Initiatives - The company signed a definitive agreement to acquire a 5% equity stake in Perfect Scripts, LLC, with an option to increase to 40%, establishing a strategic partnership [5][10] - Hydreight is actively evaluating profitable multi-state wellness and digital health operators for potential acquisitions to scale nationally through the VSDHOne platform [5][10] - The upcoming release of VSDHOne V2 aims to enhance automation, scalability, and modular functionality for partners nationwide [5][10] Recognition and Awards - Hydreight was recognized as one of Canada's Technology Fast 50™ award winners and ranked 77 among the fastest-growing companies in North America on the 2025 Deloitte Technology Fast 500™ [5][10]

Core Insights - Hydreight Technologies Inc. ranked No. 77 on the 2025 Deloitte Technology Fast 500™, highlighting its status as one of the fastest-growing technology companies in North America [1][2] - The company's growth is attributed to the expansion of its telehealth and pharmacy infrastructure, as well as the rapid onboarding of partners to its VSDHOne direct-to-consumer platform [2] - Hydreight previously ranked 56 on the 2024 Deloitte Technology Fast 500™ and 9 on Deloitte's 2024 Technology Fast 50™ (Canada) [2] Company Overview - Hydreight is building a large mobile clinic network in the United States, with a platform that includes over 3,000 nurses and 200 doctors across all 50 states [6][7] - The platform offers integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, enabling healthcare professionals to provide services directly to patients [7] - The company has a 503B pharmacy network and is affiliated with a certified e-script and telemedicine provider network [7] VSDHOne Platform - The VSDHOne platform simplifies entry for healthcare and wellness brands into the online space, allowing them to launch nationwide in days [8] - Compliant offerings include GLP-1s, peptides, personalized healthcare treatments, and more [8] - The platform provides a complete solution for businesses looking to enter the direct-to-consumer healthcare market, significantly reducing time and costs associated with launching services [8] Industry Context - The 2025 Technology Fast 500 companies achieved revenue growth ranging from 122% to 29,738%, with an average growth rate of 1,079% over three years [3] - The Deloitte Technology Fast 500™ has been recognizing fast-growing companies for 31 years, emphasizing the agility of private enterprises in competitive markets [4]

Core Insights - Hydreight Technologies Inc. has reported significant growth, processing over 295,000 VSDHOne product orders from July to September 2025, indicating a robust expansion in its nurse network and a strong financial position with approximately CA$18.7 million in cash [1][6][9]. Company Performance - The company ranked 25 on Deloitte's 2025 Technology Fast 50™ in Canada for revenue growth from 2021 to 2024, and previously ranked 56 on Deloitte's 2024 Technology Fast 500™ in the U.S., highlighting its leadership in modernizing healthcare delivery through technology [3][6]. - Hydreight operates one of the largest compliant telehealth and medical networks in the U.S., connecting healthcare providers, pharmacies, and patients through its VSDHOne platform across all 50 states [4][13]. Recent Highlights - The company saw a 49% year-over-year increase in new nurse sign-ups, with 198 new sign-ups between July and September 2025 compared to 133 in the same period last year, and a total of 593 sign-ups in the first nine months of 2025, up from 364 in 2024 [9]. - Pharmacy orders, excluding VSDHOne, increased approximately 72% year-over-year, reflecting sustained growth across multiple wellness verticals [9]. Financial Position - Hydreight enhanced its liquidity with an oversubscribed CA$11.5 million convertible debenture financing closed on September 4, 2025, bringing its cash position to approximately CA$18.7 million as of October 22, 2025 [9][12]. - The company is focused on profitable and compliant expansion, aiming to create long-term shareholder value while scaling its telehealth infrastructure nationally [12]. Strategic Initiatives - The company is actively integrating 503A/503B pharmacy partners to improve capacity, fulfillment speed, and margin potential, alongside the upcoming release of VSDHOne V2, which will enhance automation and scalability [9]. - Hydreight is expanding its GLP-1 program and direct-to-consumer wellness offerings, with ongoing national rollout initiatives [10][9]. Industry Recognition - Hydreight has been recognized as a Top 50 TSX Venture Exchange Company for 2024 and selected as a finalist for the Company of the Year – Scale Award at the BC Tech Association's 2025 Technology Impact Awards [8].

Core Insights - Hydreight Technologies Inc. has reported significant growth in product orders and nurse network expansion, with over 295,000 VSDHOne product orders processed between July and September 2025, indicating a strong demand for its services [1][9] - The company has a robust cash position of approximately CA$18.7 million, positioning it well for future growth initiatives [6][9] - Hydreight has received multiple recognitions for its rapid growth and innovation, including being ranked 25 on Deloitte's 2025 Technology Fast 50™ in Canada [3][8] Company Performance - The company processed ~295,000 VSDHOne product orders from July to September 2025, reflecting broad growth across various wellness verticals [9] - Nurse network expansion saw 198 new nurse sign-ups in Q3 2025, a 49% increase year-over-year, and a total of 593 sign-ups in the first nine months of 2025, up ~63% from 2024 [9] - Pharmacy orders, excluding VSDHOne, increased approximately 72% year-over-year, indicating sustained growth and broader adoption [9] Financial Position - Hydreight's liquidity was enhanced by an oversubscribed CA$11.5 million convertible debenture financing closed on September 4, 2025, bringing cash reserves to approximately CA$18.7 million as of October 22, 2025 [9] - The company is focused on profitable and compliant expansion, aiming to create long-term shareholder value [12] Strategic Developments - Hydreight is actively integrating 503A/503B pharmacy partners to improve capacity and fulfillment speed, alongside the upcoming release of VSDHOne V2, which will enhance automation and scalability [9] - The company is rolling out Dr. Franklin Joseph's GLP-1 program nationally to meet increasing patient demand [10] - Hydreight is evaluating potential mergers and acquisitions of profitable multi-state wellness and digital health operators to scale nationally [9] Industry Recognition - Hydreight was recognized as a Top 50 TSX Venture Exchange Company for 2024 and was a finalist for the Company of the Year – Scale Award at the BC Tech Association's 2025 Technology Impact Awards [8] - The company has been acknowledged for its leadership in modernizing healthcare delivery through technology and compliance [3]

Core Insights - Hydreight Technologies Inc. has reported stronger-than-expected order growth and strategic advancements, indicating a robust performance in the mobile clinical network sector [1][2][3] Order Growth and Market Momentum - In August 2025, Hydreight processed over 80,000 pharmacy and telehealth product orders, exceeding the internal forecast of approximately 55,000 orders, reflecting broad demand across multiple service lines [2] - The company has seen an 86% year-over-year increase in pharmacy orders from January to August 2025, indicating significant market momentum [3] Strategic Growth Initiatives - Hydreight has invested in making the VSDHOne platform fully modular, enhancing customer adoption and expanding its total addressable market [4] - The company reported a 33% year-over-year revenue growth for H1 2025, marking its third consecutive quarter of profitability, driven by strong pharmacy order growth and network expansion [4] - An oversubscribed financing round raised $11.5 million to support strategic initiatives and strengthen the balance sheet [4] - The acquisition of a 5% stake in Perfect Scripts LLC aims to enhance operational control over pharmacy fulfillment and support margin expansion [4] AI Integration - Hydreight is in due diligence to acquire an AI-driven tool designed to provide personalized IV treatment recommendations, which is expected to enhance clinical decision-making and marketing capabilities [5] Customer Lifetime Value (LTV) Expansion - The company is focusing on expanding Customer Lifetime Value (LTV) by encouraging patients to engage with multiple service offerings within its ecosystem, thereby deepening patient relationships and improving unit economics [6] Outlook - Management emphasizes the need for continued investment in infrastructure, technology, and regulatory compliance to sustain growth, particularly in integrating new acquisitions [7] Competitive Position - Hydreight believes its established provider network, expanding pharmacy relationships, and growing patient demand position it favorably in the fragmented U.S. digital health market [8] Management Commentary - The CEO highlighted the broad-based adoption of Hydreight's services across various healthcare segments, indicating a strong platform performance [9] - The company is committed to building a scalable and compliant model that delivers value to patients, providers, and shareholders [10]

Core Viewpoint - Hydreight Technologies Inc. has entered into a strategic partnership with Perfect Scripts LLC, which includes acquiring a 5% membership interest in Perfect Scripts and establishing a 503B pharmacy in the U.S. [1][2] Company Overview - Hydreight Technologies Inc. operates a fully integrated mobile clinical network in North America, comprising over 2,500 nurses and 100 doctors, along with a pharmacy network across all 50 states [13][14]. - Perfect Scripts LLC is the parent company of PerfectRx LLC and PerfectionRx LLC, which operate pharmacies and provide pharmaceutical services [6][9]. Transaction Details - Hydreight will acquire a 5% membership interest in Perfect Scripts for 2,250,000 common shares, with a deemed price of CAD$2.30 per share or the lowest price permitted by the TSX Venture Exchange [2]. - The partnership will allow Hydreight to receive the lowest pricing for products sold by Perfect Scripts and grants the right to maintain and increase its membership interest up to 40% [2][3]. Financial Aspects - A cash finder's fee of $258,750 will be paid to a finder in connection with the transaction, representing 5% of the deemed value [3]. - The Hydreight Compensation Shares will vest in increments and are subject to a four-month statutory hold period under Canadian securities laws [4][5]. Strategic Implications - The partnership is expected to enhance Hydreight's pharmacy margins, secure a consistent supply chain, and provide vertical integration, which will strengthen its market position [6][8]. - The U.S. compounding pharmacy sector is projected to grow from $6.31 billion in 2024 to $10.76 billion by 2033, indicating significant market potential for Hydreight and Perfect Scripts [8]. Operational Capabilities - PerfectRx LLC operates a 30,000 sq ft licensed pharmacy and distribution center in Florida and can process over 150,000 prescriptions per day [7][10]. - The proprietary technology, PerfectOS, enables efficient digital prescription intake and real-time inventory management, enhancing operational efficiency [10][11]. Future Outlook - The partnership is viewed as a critical step in transforming access to modern healthcare and expanding Hydreight's product lineup [8]. - The VSDHOne platform, developed in partnership with Victory Square Technologies, aims to simplify the entry for companies into the online healthcare space, further supporting Hydreight's growth strategy [15].

Core Insights - Hydreight Technologies Inc. has reported record-breaking growth in orders for its VSDHOne platform, with July orders significantly exceeding projections and August tracking ahead of schedule towards a goal of 1.3 million total orders for 2025 [2][4] - The partnership with Perfect Scripts and the introduction of 503B compounding capabilities are expected to enhance the scalability, efficiency, and reach of the VSDHOne platform [4][7] - The launch of Hydreight Marketing Solutions aims to drive client growth and increase order volume across the VSDHOne network by providing marketing services tailored for healthcare providers [8][9] Order Growth - VSDHOne platform achieved approximately 7,187 SKU orders in June 2025, surpassing the internal forecast of 7,000–10,000 SKU orders [6] - In July 2025, the platform achieved approximately 35,642 SKU orders, over three times the internal forecast of around 10,000 SKU orders [6] - The internal forecast for August 2025 aims for approximately 55,000 SKU orders [6] Technology and Integration - Hydreight is enhancing the VSDHOne technology platform into a fully modular architecture, allowing businesses to adopt only the necessary components for order generation [3] - Perfect Scripts' technology integrates directly with VSDHOne, automating prescription processing and significantly reducing fulfillment times [7] - The 503B compounding capability allows Hydreight to manufacture and ship high-demand medications at scale, overcoming the limitations of traditional compounding methods [7] Marketing Solutions - Hydreight Marketing Solutions will provide data-driven campaigns and patient acquisition strategies specifically for healthcare providers on the VSDHOne platform [8] - The initiative is expected to drive significant growth, as successful marketing at the client level translates to higher patient volumes and order growth across the network [9] - The goal is to empower partners to market effectively, increasing patient engagement and revenue for all involved [9] Corporate Update - Gabi Kabazo has resigned as a director effective August 8, 2025, to focus on other professional commitments [10] - Hydreight Technologies Inc. has been recognized as the 56th fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™ [11]